BNP Paribas Arbitrage SNC trimmed its position in shares of DaVita Inc. (NYSE:DVA – Free Report) by 2.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 464,187 shares of the company’s stock after selling 9,659 shares during the quarter. BNP Paribas Arbitrage SNC’s holdings in DaVita were worth $46,637,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently bought and sold shares of DVA. BlackRock Inc. boosted its stake in shares of DaVita by 5.4% during the first quarter. BlackRock Inc. now owns 5,083,162 shares of the company’s stock valued at $412,295,000 after purchasing an additional 260,783 shares during the period. Norges Bank purchased a new stake in shares of DaVita during the fourth quarter valued at $116,373,000. Morgan Stanley boosted its stake in shares of DaVita by 37.9% during the fourth quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock valued at $92,042,000 after purchasing an additional 339,051 shares during the period. Geode Capital Management LLC boosted its stake in shares of DaVita by 2.2% during the first quarter. Geode Capital Management LLC now owns 1,166,589 shares of the company’s stock valued at $94,411,000 after purchasing an additional 25,161 shares during the period. Finally, Lazard Asset Management LLC boosted its stake in shares of DaVita by 8.5% during the fourth quarter. Lazard Asset Management LLC now owns 857,087 shares of the company’s stock valued at $63,998,000 after purchasing an additional 67,216 shares during the period. 84.69% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
DVA has been the subject of a number of recent analyst reports. StockNews.com initiated coverage on shares of DaVita in a research note on Thursday, October 5th. They set a “buy” rating for the company. TheStreet lowered shares of DaVita from a “b-” rating to a “c” rating in a research note on Monday, October 23rd. UBS Group raised shares of DaVita from a “neutral” rating to a “buy” rating and boosted their target price for the company from $100.00 to $142.00 in a research note on Monday, August 7th. Finally, Truist Financial decreased their price objective on DaVita from $115.00 to $104.00 and set a “hold” rating for the company in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $107.50.
DaVita Stock Performance
DVA stock opened at $92.12 on Wednesday. The company has a debt-to-equity ratio of 6.01, a current ratio of 1.24 and a quick ratio of 1.19. The business has a 50-day moving average price of $87.91 and a 200 day moving average price of $95.73. The company has a market capitalization of $8.41 billion, a P/E ratio of 14.13, a PEG ratio of 0.59 and a beta of 0.98. DaVita Inc. has a 1-year low of $67.88 and a 1-year high of $116.97.
DaVita (NYSE:DVA – Get Free Report) last released its quarterly earnings data on Tuesday, November 7th. The company reported $2.85 earnings per share for the quarter, beating the consensus estimate of $1.92 by $0.93. The firm had revenue of $3.12 billion during the quarter, compared to the consensus estimate of $3.02 billion. DaVita had a return on equity of 63.38% and a net margin of 5.11%. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.45 earnings per share. As a group, equities research analysts forecast that DaVita Inc. will post 8.19 EPS for the current fiscal year.
Insiders Place Their Bets
In other DaVita news, insider Kathleen Alyce Waters sold 9,794 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $101.81, for a total value of $997,127.14. Following the completion of the transaction, the insider now directly owns 81,297 shares in the company, valued at $8,276,847.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.40% of the stock is currently owned by corporate insiders.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Five stocks we like better than DaVita
- How to Invest in Biotech Stocks
- Fisker Inc. price implosion; is it time to buy the dip?
- The Dividend Kings With Highest Yield
- The only 2 cannabis companies you need to own
- Which Wall Street Analysts are the Most Accurate?
- Is it time to buy EVOLV Technologies after post-earnings dip?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.